Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 121-132, April 2010

Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract

  • Carlos Sostres, MD (Research Fellow)

      Affiliations

    • Service of Digestive Diseases, University Hospital Lozano Blesa, Zaragoza, Spain
  • ,
  • Carla J. Gargallo, MD (Research Fellow)

      Affiliations

    • Service of Digestive Diseases, University Hospital Lozano Blesa, Zaragoza, Spain
  • ,
  • Maria T. Arroyo, MD, DSc (Permanet Staff Member)

      Affiliations

    • Service of Digestive Diseases, University Hospital Lozano Blesa, Zaragoza, Spain
    • CIBERehd, Aragon Health Sciences Institute, Zaragoza, Spain
  • ,
  • Angel Lanas, MD, DSc (Professor, Clinical Chief)

      Affiliations

    • Service of Digestive Diseases, University Hospital Lozano Blesa, Zaragoza, Spain
    • CIBERehd, Aragon Health Sciences Institute, Zaragoza, Spain
    • University of Zaragoza, Spain
    • Corresponding Author InformationCorresponding author. Servicio de Aparato Digestivo, Hospital Clínico Universitário Lozano Blesa, c/Domingo Miral s/n, 5009 Zaragoza, Spain.

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely prescribed medication in the world. Their main benefit derives from their anti-inflammatory and analgesic effect, but the use of these agents is not innocuous since they mainly increase the risk of gastrointestinal (GI) and cardiovascular complications compared with non-NSAID users. NSAIDs injures the upper and lower gut by depleting COX-1 derived prostaglandins and causing topical injury to the mucosa. The risk of upper GI complications varies, depending on the presence of one or more risk factors. Among them, the three main risk factors are prior history of peptic ulcer, the single most important risk factor, age, the most common, and concomitant aspirin use, due to their GI and cardiovascular implications. Those individuals at-risk should be considered for alternatives to NSAID therapy and modifications of risk factors. If NSAID therapy is required, patients at risk will need prevention strategies including co-therapy of NSAID with gastroprotectants (PPI or misoprostol) or the prescription of COX-2 selective inhibitors. The probable introduction of NO-NSAIDs in the market in the near future may open a new therapeutic option for patients with hypertension who need NSAIDs.

Keywords: NSAIDs, coxibs, GI damage, proton pump inhibitors

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6918(09)00158-9

doi:10.1016/j.bpg.2009.11.005

Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 121-132, April 2010